Overview

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Status:
Unknown status
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Docetaxel and sunitinib will be compared to docetaxel for their effect on CEC/CEP spikes induced by docetaxel in HRPC patients
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of Vienna
Treatments:
Docetaxel
Sunitinib